R. W. Sanders

This study identifies neutralizing antibody epitopes against Lassa virus GPC using electron microscopy, revealing challenges in vaccine-induced responses and opportunities for improved vaccine design.

This study shows that a multi-dose immunization with germline-targeting SOSIP vaccines induces precursor broadly neutralizing antibodies in infant macaques, similar to adult responses.

This study identifies broadly neutralizing monoclonal and bispecific antibodies from a Gamma variant-infected individual that effectively neutralize multiple SARS-CoV-2 variants.

The paper introduces a triple tandem trimer (TTT) design for HIV-1 Env and influenza HA immunogens, showing improved trimer-specific immune responses in viral vectored vaccines.

This study shows bispecific antibodies combine the neutralizing breadth and potency of parental antibodies to neutralize SARS-CoV and SARS-CoV-2 variants, including Omicron.

The paper structures and characterizes Lassa virus glycoproteins from multiple lineages and identifies neutralizing antibodies that target conserved epitopes.

This study develops Lassa virus glycoprotein nanoparticles that stabilize GPC trimers and elicit neutralizing antibodies targeting a new vulnerability site.

This study shows that immunization with native-like HIV-1 subtype B Env trimers can induce CD4bs-directed broadly neutralizing antibodies in rabbits.

The paper analyzes IgG1 clonal responses to SARS-CoV-2 variants in infected donors, finding unique and polyclonal antibody repertoires with varying cross-reactivity across variants.

The paper presents the cryo-EM structure of the HCV E1E2 glycoprotein complex with antibodies, revealing the E1-E2 interface and its stabilization mechanisms.

The paper identifies a novel S2 epitope recognized by a public antibody class in SARS-CoV-2-reactive B cells, which becomes exposed on vaccine-optimized spike proteins.

A mathematical model of viral dynamics is used to identify mechanistic correlates of protection in SARS-CoV-2 vaccines across three non-human primate studies.

This study shows that IDLV vectors with membrane-tethered native-like HIV-1 Env trimers induce faster and longer-lasting anti-Env IgG responses in mice and macaques, with some animals developing neutralization activity against HIV-1.

This study shows SARS-CoV-2 does not activate dendritic cells via extracellular TLRs but instead relies on intracellular sensors after infecting ACE2-expressing dendritic cells.

This study uses single particle mass analyses to examine antibody binding to the SARS-CoV-2 spike protein, revealing sub-stoichiometric binding and its effectiveness in blocking ACE2.

The paper compares glycosylation patterns of recombinant SARS-CoV-2 spike proteins across labs with infectious virus S protein, finding conserved site-specific glycan maturation stalling linked to protein structure.

The paper examines how mutations at E484 and K417 in SARS-CoV-2 variants affect neutralizing antibodies, showing reduced efficacy against certain antibody families but not others.

This study shows that combining cross-neutralizing antibodies CV38-142 and COVA1-16 enhances neutralization of SARS-CoV-2 and SARS-CoV pseudoviruses.

The paper uses cryoEM to analyze polyclonal antibody responses to HIV Env immunogens in rhesus macaques, revealing structural differences in antibody binding and immunogenicity of engineered mutations and glycan sites.

This study evaluates how Spike mutations in SARS-CoV-2 variants affect neutralization by monoclonal and polyclonal antibodies, showing reduced activity in some cases.

This study shows that displaying HIV-1 Env trimers on two-component protein nanoparticles enhances autologous Tier-2 neutralizing antibody titers in rabbits.

This study identifies heparan sulfate proteoglycans as SARS-CoV-2 attachment receptors and shows that LMWH blocks infection and transmission.

The paper identifies a SARS-CoV-2 antibody that cross-neutralizes SARS-CoV by binding a conserved epitope and relies on avidity for neutralization.

This study identifies an alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 RBD, showing that longer CDR H3 can bind with different angles and interactions.

The paper shows that the HIV-1 gp120 signal peptide remains attached during folding, enhancing conformational plasticity and ensuring only properly folded gp120 is released.

The paper modifies HIV-1 Env trimers to increase glycan occupancy and reduce artificial glycan holes, improving vaccine antigen design.

The paper shows that afucosylated IgG responses are common in enveloped virus infections and are more severe in COVID-19, with implications for immune response and pathology.

The paper investigates how HIV-1 envelope glycan networks affect the formation and stability of broadly neutralizing antibody epitopes, showing their importance in immunogen design.

This study maps antibody responses to HIV-1 envelope trimers in non-human primates, identifying strain-specific and conserved epitopes recognized by vaccine-induced antibodies.

The paper evaluates de novo-designed two-component nanoparticles for presenting HIV Env trimers, showing improved antibody responses through multivalent display.